Sorrento Therapeutics Inc (SRNE)

[runcaly]

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license and development partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), presented at this year’s Chinese Society of Clinical Oncology (CSCO) Guideline Conference (April 23-24, 2022) Phase 1 data for its anti-HER2-ADC, A166. To generate this site-specific third generation ADC, Kelun partnered with Levena Biopharma, a Sorrento company, which provided the proprietary ADC technologies for the generation and production of A166, including (1) a proprietary small molecule toxin, Duostatin-5, a tubulin inhibitor, (2) K-Lock, a site-specific conjugation chemistry and (3) an enzymatically cleavable linker. Compared to Kadcyla®, the first Antibody-Drug Conjugate approved for the treatment of HER2-positive metastatic breast cancer, A166 demonstrated potentially better efficacy, as shown in the overall response rate (ORR) of 73.9% with A166 at 4.8mg/kg versus Kadcyla®, which had an ORR of 31.3%, as well as the progression-free survival (PFS) of 12.3 months with A166 versus 6 months with Kadcyla®.